Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Pterostilbene

Pterostilbene · also known as Dimethoxy resveratrol, Pterostilbene

Pterostilbene is a dimethoxy derivative of resveratrol and is relatively fat-soluble. The claim that its oral bioavailability is higher than resveratrol’s comes mainly from animal data. Whether it directly activates SIRT1 is still disputed, and in a human randomized trial LDL-C actually rose in the group taking pterostilbene alone.

Typical dose: 50–150 mg/day, taken with a breakfast that contains fat
Absorption and forms: Pterostilbene’s half-life (about 105 minutes, versus about 14 minutes for resveratrol) and its oral bioavailability figures come mainly from animal studies and should not be used as fixed human pharmacokinetic parameters. Comparative claims such as lower first-pass liver metabolism or deeper tissue accumulation also lack reliable human data.

Clinical uses and human evidence

High blood pressure

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Riche 2014 · Evid Based Complement Alternat Med · RCT · n=80 — Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial

High LDL cholesterol

No benefitGrade B · Moderate evidence
Studies (1)
  1. Riche 2014 · Evid Based Complement Alternat Med · RCT · n=80 — Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial

Mechanisms of action

Sirtuin-dependent protein deacetylase activation

★★★☆☆Mechanism evidence: grade CSecondary target

In animal models, pterostilbene restored SIRT1 deacetylation activity and related rhythms. Whether it binds SIRT1 directly and activates it allosterically remains disputed, and upregulation of anti-aging genes has not been confirmed in humans.

References (1)
  1. 2020 · Mouse sleep restriction study: pterostilbene restored SIRT1 deacetylation activity and related rhythms

AMPK sensing of cellular energy deficit and metabolic reprogramming

★★★☆☆Mechanism evidence: grade CSecondary target

In animal models, pterostilbene can cause changes in the AMPK pathway, but LKB1 activation and a synergistic effect with PPAR-α have not been confirmed. Changes in human metabolic markers cannot prove that AMPK was activated, and the doses and disease models used in animals do not directly represent usual supplement doses.

References (1)
  1. Xu 2021 · Mouse study: after oral pterostilbene, AMPK/SIRT1 pathway markers changed in an allergic airway inflammation model

Nrf2/ARE activation of endogenous antioxidant enzymes

★★☆☆☆Mechanism evidence: grade CSecondary target

After oral pterostilbene, Nrf2/HO-1-related markers rose in mouse lung tissue. This suggests the pathway was activated, but the evidence comes from animal models. Changes in SOD and CAT activity alone cannot prove Keap1 dissociation, and whether pterostilbene binds Keap1 directly, and what effect it has in humans, remain unclear.

References (1)
  1. Xu 2021 · Mouse study: after oral pterostilbene, Nrf2/HO-1-related markers rose in lung tissue

Safety and drug interactions

In one randomized controlled trial, LDL-C rose in the group taking pterostilbene alone (Riche et al., 2014). This effect should not be dismissed as a brief change seen only in a few high-dose users. Whether adding citrus flavonoids or berberine can offset it has not been confirmed.

Related lab tests

Lipid panel Recheck while taking

A small trial found that pterostilbene taken alone (100–250 mg/day) raised LDL-C. People with cardiovascular risk should have their lipids rechecked about 2 months after starting it.

Open in the interactive app ›